Xanadu Bio, Inc. is a biotechnology company that develops next-generation polymer nanoparticle delivery platforms for mRNA and other nucleic acid-based therapies. Utilizing its proprietary poly(amine-co-ester) (PACE) polymer technology, the company creates tunable, organ-specific treatments for oncology and immunology, as well as intranasal vaccines for viral respiratory pathogens.
Subscribe to see Xanadu Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Xanadu Bio, Inc. is a biotechnology company headquartered in Gladwyne, United States. Its most recent funding round raised $11M in August 2025. Xcout tracks 13 named people at Xanadu Bio, Inc., including Bruce Turner (Chief Executive Officer & President of the Issuer).
As of 16 November 2026. Source: Xcout Intel.
7 more named people on record for Xanadu Bio, Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $11M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Xanadu Bio, Inc.'s closest competitors — see the full list of competitors and alternatives →
HelixNano is a biotechnology research company headquartered in Boston, Massachusetts, focused on developing advanced mRNA platform technologies for therapeutics.
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Combined Therapeutics is a biotechnology company that develops next-generation mRNA vaccines and immunotherapies for infectious diseases and oncology. The company utilizes a proprietary mRNA platform featuring microRNA binding sequences to target therapeutic protein expression in specific tissues while protecting vital organs from off-target effects.
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Phoreus Biotechnology, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Olathe, Kansas. The company specializes in the development of proprietary nanocarriers for targeted drug delivery and enhanced treatments.
Paean Holdings, Inc. (operating as PAEAN Biotechnology) develops mitochondria-based therapeutics designed to treat rare diseases, inflammatory conditions, cancer, and central nervous system disorders. The company utilizes proprietary platforms including mitochondrial transplantation, modified mitochondria for targeted delivery, and mitochondria-augmented cell therapy to address critical medical needs and overcome cellular metabolic limitations.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Xanadu Bio, Inc.? Suggest a correction · Work at Xanadu Bio, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.